B12 absorption older adults: Wang et al., 2026
A 2026 observational study of 275 ambulatory adults with cirrhosis found that 34% of frail patients were B12-deficient versus 18% of non-frail patients. This is an association study in a diseased population — it cannot establish that B12 causes frailty, nor that supplementation reverses it. The finding is plausible (cirrhosis impairs intrinsic factor and bile acids needed for B12 absorption), but generalization to healthy older adults requires caution.
Key takeaways
- Among 275 ambulatory cirrhosis patients awaiting transplant, 25% were B12-deficient — significantly higher in frail patients (34%) than non-frail (18%).
- B12 deficiency showed 2.56 increased odds of frailty in univariable analysis, but this association disappeared when controlling for confounders.
- Selenium deficiency was the only micronutrient independently associated with frailty after adjustment (OR 2.55).
- This is an observational study — it identifies correlation, not causation. We cannot know if B12 supplementation would reverse frailty without an intervention trial.
- Cirrhosis is a disease of malabsorption — findings in this population do not translate directly to healthy older adults, who have different B12 absorption physiology.
The study
Wang et al. published this observational study in Hepatology Communications in 2026 (PubMed). They enrolled 275 ambulatory adults with cirrhosis awaiting liver transplant at a single center from June 2024 to March 2025. Median age was 60 years, 42% were women, and 23% met criteria for frailty. Researchers measured serum levels of zinc, vitamins A/D/E/B12, and selenium as part of routine clinical practice, then assessed statistical associations between micronutrient deficiencies and frailty status using multivariable logistic regression. This was a cross-sectional design — all measurements taken at a single time point. The authors did not intervene with supplementation or follow patients longitudinally to see if correcting deficiencies changed frailty outcomes.
How to read this study
What this paper does well: The sample size of 275 patients is solid for an observational study. The authors controlled for confounders in their multivariable models — age, sex, MELD score (liver disease severity), albumin, and BMI — which is the correct approach to isolate independent associations. They tested a defined panel of micronutrients rather than cherry-picking, and they reported both univariable and adjusted odds ratios with confidence intervals, which lets us see what disappeared after adjustment. That transparency is methodologically honest.
What this paper is missing: This is a cross-sectional snapshot — we don't know if B12 deficiency preceded frailty or resulted from it. Frail patients may eat less, absorb less, or have more advanced disease driving both outcomes. The study measured serum B12, which is a surrogate marker — it correlates with functional B12 status but doesn't directly measure methylmalonic acid or homocysteine (the metabolites that confirm tissue-level deficiency). Most critically, this is a cirrhosis population. Cirrhotic livers produce less intrinsic factor, bile acid secretion is impaired, and gut bacteria overgrowth is common — all mechanisms that disrupt B12 absorption. Healthy older adults have age-related achlorhydria but not these additional liver-driven barriers.
How I weight this paper: I treat this as a plausibility flag for the B12-frailty link in older adults, not as evidence that applies directly to them. The fact that B12's association with frailty vanished after adjustment (while selenium's persisted) suggests B12 may be a marker of disease severity rather than an independent driver. If you're extrapolating to healthy older men, this paper doesn't move the needle much. If a well-powered RCT in healthy older adults showed B12 supplementation reverses frailty markers, I'd weight that heavily. This observational study in a diseased population — minimally.
What they found
Micronutrient deficiencies were common across the cohort: 34% zinc-deficient, 25% B12-deficient, 24% vitamin E-deficient, 18% selenium-deficient, 16% vitamin D-deficient, 15% vitamin A-deficient. Among the 64 frail patients, 34% were B12-deficient versus 18% of the 211 non-frail patients (p=0.01). Vitamin E deficiency was present in 36% of frail patients versus 20% of non-frail (p=0.02). Selenium deficiency was present in 28% of frail versus 13% of non-frail (p=0.01).
On univariable analysis, B12 deficiency was associated with 2.56 increased odds of frailty (95% CI: 1.04-6.20). Vitamin E deficiency showed 2.55 increased odds (95% CI: 1.06-6.11). Selenium deficiency showed 3.00 increased odds (95% CI: 1.15-7.68). However, after controlling for age, sex, MELD score, albumin, and BMI in multivariable models, only selenium deficiency remained independently associated with frailty (adjusted OR: 2.55, 95% CI: 1.18-5.54, p=0.02). The associations for B12 and vitamin E disappeared after adjustment, suggesting they were confounded by disease severity or other factors.
What it means for the average man
If you have cirrhosis awaiting transplant, this study suggests routine micronutrient testing is warranted — deficiencies are common and selenium deficiency in particular tracks with frailty independent of liver disease severity. For the average healthy man over 50, the takeaway is more limited. B12 deficiency is plausible as a frailty contributor in older adults (it impairs nerve function, red blood cell production, and homocysteine metabolism), but this study doesn't prove causation or demonstrate that supplementation helps. The fact that the B12-frailty association vanished after adjustment raises the possibility that it's a marker of sicker patients, not a driver of frailty itself. If you're supplementing B12 for neurological or hematological support, this paper doesn't argue against it. But it also doesn't provide strong evidence that B12 supplementation will prevent or reverse frailty in men without liver disease.
The caveats
This is an observational study in a diseased population — both major limitations for generalization. Cirrhosis disrupts nutrient absorption through multiple mechanisms (reduced intrinsic factor, impaired bile secretion, gut bacterial overgrowth, portal hypertension) that don't apply to healthy older adults. The cross-sectional design cannot establish temporal sequence — we don't know if B12 deficiency preceded frailty or resulted from the same disease progression. The study measured serum B12, not the gold-standard functional markers (methylmalonic acid, homocysteine). The authors did not test whether correcting deficiencies reversed frailty. No randomized intervention, no causality established. The confidence intervals for B12's odds ratio were wide (1.04-6.20), reflecting statistical uncertainty. Industry funding was not disclosed, though this was conducted at a single academic center as part of routine clinical practice.
Frequently asked questions
Does this study prove B12 deficiency causes frailty?
No. This is an observational study showing an association that disappeared after controlling for confounders. Association is not causation. To establish causation, you'd need a randomized controlled trial showing that B12 supplementation reverses frailty in deficient patients. This study didn't intervene — it only measured correlations at a single time point.
Why did the B12 association disappear after adjustment?
Because the multivariable model controlled for confounders like MELD score (liver disease severity) and albumin (a marker of synthetic liver function and nutritional status). If B12 deficiency is simply more common in sicker patients — who are also more likely to be frail for other reasons — then the association isn't independent. The statistical disappearance suggests B12 may be a marker of disease severity rather than an independent cause of frailty.
Can I apply this to healthy older adults?
With caution. Cirrhosis impairs B12 absorption through mechanisms that don't exist in healthy aging — reduced intrinsic factor production, bile acid disruption, bacterial overgrowth. Healthy older adults do have age-related achlorhydria (low stomach acid), which impairs B12 absorption from food but not from supplements. The biological plausibility exists, but this study's population is too different to generalize directly.
Should I trust a cross-sectional study?
Cross-sectional studies are useful for identifying associations and generating hypotheses, but they cannot establish causation. They measure everything at one time point — you can't know what came first. A longitudinal study tracking B12 levels and frailty over time would be stronger. A randomized trial testing supplementation would be strongest.
Sources
- Wang M, Pariani K, Barry F, Kent D, Seetharaman S, Catalli L, et al. Micronutrient deficiencies in ambulatory adults with cirrhosis. Hepatology Communications. 2026. PubMed
- Allen LH. How common is vitamin B-12 deficiency? Am J Clin Nutr. 2009;89(2):693S-696S.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
